#USA #Columbus #CAS #Novartis #reaction data

CAS and Novartis Collaboration to Revolutionize Reaction Informatics

In a significant advancement for scientific data management, CAS, a division of the American Chemical Society, has announced an exciting collaboration with Novartis Biomedical Research. This partnership aims to enhance the accessibility of reaction data and leverage artificial intelligence (AI) to transform the way researchers access and analyze experimental information.

Advancing Data Accessibility

The initiative emphasizes providing researchers with an integrated and searchable database that includes exclusive experimental data on reactions, complemented by over 160 million scientifically validated reactions from the CAS Content Collection™. The collaboration seeks to overcome current challenges faced by researchers in sourcing reaction data, which is often scattered across various systems like electronic lab notebooks and shared drives. By consolidating these insights, CAS and Novartis aim to facilitate more effective and efficient analysis of reaction data, ultimately accelerating the research process in the field of drug discovery.

Tim Wahlberg, interim president of CAS, highlighted the significance of such collaborations in an era where data infrastructure plays a crucial role in scientific advancements. He stated, "This exciting collaboration underscores the vital importance of a strong scientific data infrastructure paired with domain-specific technology and expertise, particularly as drug discovery processes continue to evolve rapidly. Our ongoing partnership with Novartis contributes to making these vital data resources more accessible and usable for AI applications."

Tailored Research Platform

In addition to improving data accessibility, CAS will work closely with Novartis to build a customized research platform based on the CAS SciFinder® architecture. This new platform is designed to allow Novartis researchers to concurrently search, analyze, and cross-reference their internal data with CAS reaction data. This approach aims to address long-standing challenges associated with efficiently searching for both internal and external data, setting the groundwork for future innovations, including advanced language models and autonomous AI capabilities.

Impact on Scientific Community

The collaboration between CAS and Novartis stands to revolutionize the research landscape by providing a solid infrastructure for reaction data management. With an ever-growing need for actionable insights, the platform seeks to equip researchers with the tools necessary to harness the full potential of AI and machine learning in their studies. Researchers will benefit from streamlined access to critical data, resulting in faster and more informed decision-making during the drug discovery process.

About CAS

CAS is dedicated to connecting the world's scientific knowledge to accelerate advancements that improve lives. As a leading data analytics partner, CAS helps innovators leverage AI's potential for real-world outcomes. Boasting the world's most extensive collection of curated scientific data, CAS underpins its analytics platforms with a foundation that fosters reliable decision-making and accurate projections in R&D processes. Their unique expertise at the intersection of scientific data and AI-driven research positions CAS to enable transformative innovation in the life sciences, chemistry, and materials sciences.

For further information or media inquiries, please contact:
Peter Carlton
Senior Communications Lead, CAS
Email: [email protected]